BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16039868)

  • 1. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expanding role for mTOR in cancer.
    Guertin DA; Sabatini DM
    Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK; Yang X; Thor AD; Somasundaram K
    Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ; Rudin CM
    Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
    Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.
    Wei C; Amos CI; Zhang N; Wang X; Rashid A; Walker CL; Behringer RR; Frazier ML
    Clin Cancer Res; 2008 Feb; 14(4):1167-71. PubMed ID: 18281551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
    Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
    Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
    Georgakis GV; Younes A
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
    Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.
    Fang P; Hwa V; Rosenfeld RG
    Exp Cell Res; 2006 May; 312(8):1229-39. PubMed ID: 16427044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.